Surgery Doctors in Fort Riley, KS Accepting Medicare

4 Surgery doctors found. Showing 1 - 4

Patricia A Keefe, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 785-239-7151    Fax: 785-240-7438

Dr. Stephen Andrew Lawson, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 270-300-0971

Dr. Daniel Robert Perry, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 785-239-7854

Dr. William Van Rice Jr., M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: Irwin Army Community Hospital, 600 Caisson Hill Rd Attn Surgery, Fort Riley, KS 66442 Phone: 785-239-7163    Fax: 785-239-7023

News Archive

PrEP raises questions regarding 'risk disinhibition' and drug resistance

Nature News reports on "the possibility of unintended public-health consequences" of pre-exposure prophylaxis (PrEP) for HIV and pharmaceutical company Gilead's plan to ask the FDA to evaluate its combination antiretroviral (ARV) drug Truvada for use in healthy people.

DSM Biologics partners with Australian Governments to build cGMP mammalian CMO

DSM Biologics is pleased to announce the signing of preliminary agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.

Study offers a differentiated patient-specific solution in minimal residual disease testing

Exact Sciences Corp. today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

Oncotype DX assay linked to decrease in chemotherapy use in younger patients

In what's believed to be one of the largest population-based studies of Oncotype DX ever conducted, researchers at The University of Texas MD Anderson Cancer Center have found that the commercial diagnostic tool, Oncotype DX, was associated with a decrease in chemotherapy use in younger patients, but not in those over 66 years of age.

Read more Medical News

› Verified 4 days ago